Global Pharmacovigilance for Antiretroviral Drugs
Author Information
Author(s): Bakare Nyasha, Edwards Ivor Ralph, Stergachis Andy, Pal Shanthi, Holmes Charles B., Lindquist Marie, Duncombe Chris, Dodoo Alex, Novendstern Joel, Nwokike Jude, Kuchenbecker Ricardo, Aberg Judith A., Miller Veronica, Strobos Jur
Primary Institution: Forum for Collaborative HIV Research and Johns Hopkins Bloomberg School of Public Health
Hypothesis
How can a sustainable global pharmacovigilance system for antiretroviral drugs be created in resource-limited settings?
Conclusion
The study highlights the need for collaboration among stakeholders to establish a sustainable global pharmacovigilance system for antiretroviral drugs.
Supporting Evidence
- Over 5 million people worldwide have access to antiretroviral drugs.
- Pharmacovigilance is essential for safe and effective drug usage.
- Contrasting priorities among stakeholders are barriers to establishing a global pharmacovigilance system.
- Understanding and respect for different stakeholder values can enhance collaboration.
Takeaway
This study talks about how important it is to keep track of the safety of medicines for people with HIV, especially in places that don't have a lot of resources.
Methodology
The study involved discussions among key stakeholders from various sectors to identify barriers and opportunities for a global pharmacovigilance system.
Potential Biases
Potential bias from stakeholders with vested interests in the pharmaceutical industry.
Limitations
The study may not fully represent the views of all stakeholders involved in pharmacovigilance.
Participant Demographics
Participants included representatives from UN agencies, government, academia, and the pharmaceutical industry.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website